The OECD holds a roundtable on generic pharmaceuticals and competition

Executive summary, by the Secretariat * Considering the roundtable discussion and the delegates’ written contributions, the following key points emerge: (1) The existence of originator drugs and innovation by originator companies is vital to develop new treatments against different illnesses and diseases. Following originator innovation, generic substitutes increase competition and result in lower drug prices, which contribute to the reduction of public healthcare expenditure. That is why governments often use a variety of tools to promote generic competition. However, certain regulatory measures may have restrictive effects and should be reformed to promote originator-generic drug competition. The pharmaceutical industry is an innovative, high-technology and I.P.-sensitive industry

Access to this article is restricted to subscribers

Already Subscribed? Sign-in

Access to this article is restricted to subscribers.

Read one article for free

Sign-up to read this article for free and discover our services.

 

PDF Version

Author

  • OECD - Competition Division

Quotation

OECD, The OECD holds a roundtable on generic pharmaceuticals and competition, 18 June 2014, e-Competitions Bulletin June 2014, Art. N° 85580

Visites 77

All issues

  • Latest News issue 
  • All News issues
  • Latest Special issue 
  • All Special issues